Bloomberg Absolute Valuation Toolkit Presentation Thoroughly analyze your stock using either Bloomberg's DDM or XLTP XDCF models. Ensure to analyze and update key inputs such as the long$-$term growth rate and its BETA Demonstrate whether your stock is under or overvalued $\backslash$begin$\{$tabular$\}\{|$c$|$c$|$c$|$c$|$c$|\}\backslash$hline & A & B & C & D $\backslash \backslash \backslash$hline $1$ & Stock & Current Price & Estimated Price & Percent Over or Under Valued $\backslash \backslash \backslash$hline $2$ & & & & $\backslash \backslash \backslash$hline $3$ & MO & $43\mathrm{.}74$ & $57\mathrm{.}17$ & $30\mathrm{.}70416095\backslash \backslash \backslash$hline $4$ & & & & $\backslash \backslash \backslash$hline $5$ & ABSOLUTE VALUE & $69\mathrm{.}4725$ & & $\backslash \backslash \backslash$hline $6$ & DDM & $82\mathrm{.}42$ & & $\backslash \backslash \backslash$hline $7$ & ANR & $46\mathrm{.}74$ & & $\backslash \backslash \backslash$hline $8$ & PG & $98\mathrm{.}15$ & & $\backslash \backslash \backslash$hline $9$ & EBITDA MULT & $50\mathrm{.}58$ & & $\backslash \backslash \backslash$hline $10$ & & & & $\backslash \backslash \backslash$hline $11$ & Relative Value & $44\mathrm{.}792$ & & $\backslash \backslash \backslash$hline $12$ & BF P$/$E & $43\mathrm{.}75$ & & $\backslash \backslash \backslash$hline $13$ & EV$/$EBITDA & $46\mathrm{.}19$ & & $\backslash \backslash \backslash$hline $14$ & EV$/$EBIT & $44\mathrm{.}32$ & & $\backslash \backslash \backslash$hline $15$ & $|$EV$/$REV & $45\mathrm{.}21$ & & $\backslash \backslash \backslash$hline $16$ & P$/$CF & $44\mathrm{.}49$ & & $\backslash \backslash \backslash$hline $17$ & & & & $\backslash \backslash \backslash$hline $18$ & Absolute and Relative & $57\mathrm{.}13225$ & & $\backslash \backslash \backslash$hline $19$ & & & & $\backslash \backslash \backslash$hline $20$ & NKE & $94$ & $99\mathrm{.}95925$ & $6\mathrm{.}33962766\backslash \backslash \backslash$hline $21$ & & & & $\backslash \backslash \backslash$hline $22$ & ABSOLUTE & & $84\mathrm{.}3025$ & $\backslash \backslash \backslash$hline $23$ & DDM & $64$ & & $\backslash \backslash \backslash$hline $24$ & PGM & $111\mathrm{.}8$ & & $\backslash \backslash \backslash$hline $25$ & EBITDA MULT & $160\mathrm{.}3$ & & $\backslash \backslash \backslash$hline $26$ & ANR & $1\mathrm{.}11$ & & $\backslash \backslash \backslash$hline $27$ & & & & $\backslash \backslash \backslash$hline $28$ & RELATIVE & & $115\mathrm{.}616$ & $\backslash \backslash \backslash$hline $29$ & PF P$/$E & $114\mathrm{.}8$ & & $\backslash \backslash \backslash$hline $30$ & BF EV$/$EBITDA & $115$ & & $\backslash \backslash \backslash$hline $31$ & EV$/$EBIT & $111\mathrm{.}4$ & & $\backslash \backslash \backslash$hline $32$ & EV$/$REV & $116\mathrm{.}5$ & & $\backslash \backslash \backslash$hline $33$ & P$/$CF & $120\mathrm{.}38$ & & $\backslash \backslash \backslash$hline $\backslash$end$\{$tabular$\}$